key: cord-0928892-jci14yo6
authors: Chatterjee, Sudipto
title: Important Steps to Control COVID-19/SARS-CoV-2 Infection
date: 2020-04-08
journal: SN Compr Clin Med
DOI: 10.1007/s42399-020-00271-7
sha: 57fc9f353a84acb7e2e1ba064cc33be4fa6cc928
doc_id: 928892
cord_uid: jci14yo6

Elderly patients are having high mortality rates from COVID-19/SARS-CoV-2 infection compared to younger patients. The SARS-CoV-2 virus uses the ACE2 receptor as the entry point to the host cells. ARBs/ACEIs which are widely used in elderly patients, have been found to be associated with overexpression of ACE2.To decrease the severity of COVID-19 infection, ARB/ACEI should be switched to another class drug not known to cause a rise in ACE2 until the COVID-19 infection subsides. Specific human immunoglobulin can be tried for COVID-19 patients with critical conditions under supervision.

On 11 March 2020, the WHO informed that COVID-19/ SARS-CoV-2 can be characterized as a pandemic. Hoffmann et al. found that SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) for host cell entry [1] . Elderly people are found to be more susceptible to this infection [2] . This indicates a possible link in elderly patients of increased ACE2 levels to some preexisting comorbid conditions. Zhang et al. found that the common comorbid conditions associated with COVID-19/SARS-CoV-2 were hypertension and diabetes mellitus [3] . Earlier studies by Wang et al. and Furuhashi et al. have found that angiotensin II receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) have been associated with overexpression of ACE2. This points towards a possible link between the severity of COVID-19 and use of ARB and ACEI [4, 5] . [5] . ARB and ACEI are widely used as one of the first-line drugs in hypertensive diabetic patients, diabetic nephropathy, and congestive cardiac failure, etc. These are very commonly witnessed comorbidities associated with many elderly patients. Hoffmann et al. found that SARS-CoV-2 uses the ACE2 as a receptor to enter the host cell, and the presence of overexpression of ACE2 can lead to a more severe form of COVID-19 infection [1] . This might be a possible explanation of why elderly patients with hypertension and diabetes are more affected by SARS-CoV-2 and why mortality rates are higher among them [6] .

Many patients are also recovering from the current COVID-19 pandemic. The collection of specific human immunoglobulin from them and using the same for critically ill patients under strict supervision can be a life-saving measure. Earlier, Cheng et al. had found promising results using convalescent plasma therapy in SARS patients in Hong Kong [7] . My hypothesis is specific human immunoglobulin may be used as a standard protocol of therapy for any unknown viral pandemic.

In conclusion, the following steps need to be taken urgently to slow down and reduce the severity of this ongoing COVID-19 pandemic: 

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy

Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker

Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China

Use of convalescent plasma therapy in SARS patients in Hong Kong